- Incoming Board Member, Michael Forbes
Incoming Board Member, Michael Forbes
Source: Forbes Pharmacies
  • PharmaDrug (CSE:BUZZ) has appointed Michael Forbes to the company’s board effective immediately
  • In his previous career, Michael has built dozens of medical clinics, owned and operated a chain of pharmacies and was at the forefront of legalising methadone clinics in British Columbia
  • He has also founded five Concord Medical Clinics, along with a cannabis production facility named Sitka Weed Works
  • Making way for Michael is Jim Frazier who will step down from the board effective immediately
  • PharmaDrug (BUZZ) is in the grey and is trading at C$0.05 per share

PharmaDrug (CSE:BUZZ) has appointed Michael Forbes to the company’s board effective immediately.

Michael has a formidable resume, having built dozens of medical clinics, owned and operated a chain of pharmacies, and was at the forefront of legalising methadone clinics in British Columbia.

Michael has also created the Ageless Living brand, which includes a wellness centre that offers a range of beauty and wellness treatments.

He helped create the standard procedures for methadone maintenance for the College of Pharmacists of British Columbia, which in turn informed the Government of British Columbia’s related procedures.

He has also founded five Concord Medical Clinics, along with a cannabis production facility named Sitka Weed Works.

Along with all of this, he has built and opened 14 Choom Cannabis locations, owns and operates the clarity cannabis chain and is launching the brand Honeycomb Cannabis.

His company, The Forbes Group, operates across western Canada and has invested into a range of sectors, including real estate, cannabis and breweries.

Making way for Michael is Jim Frazier who will be stepping down from the board effective immediately.

Daniel Cohen, CEO and Chairman of PharmaDrug said he was absolutely thrilled to have added Michael to the board.

“Michael’s unique combination of experience in pharmacy, clinic and dispensary development make him a perfect fit with our strategy to roll up smart shops in The Netherlands.

“Michael’s support of natural based medicines are made evident with his success in the cannabis field and we are excited by his enthusiasm towards the sprouting psychedelic industry,” he said.

PharmaDrug (BUZZ) is in the grey and is trading at C$0.05 per share at 12:15 pm EDT. 

More From The Market Online

The Market Online’s Weekly Cannabis Report – April 19, 2024

Cannabis news this week: Canopy Growth shareholders overwhelmingly voted to approve a new class of exchangeable shares.

Buzz on the Bullboards: Challenges amid inflation and geopolitical tensions

Canadian and U.S. stock markets grapple with a host of challenges, from surging inflation data to escalating tensions in the Middle East.

Xebra Brands receives second CBD approval by Mexican authority

Xebra Brands (CSE:XBRA) announces it has received its second COFEPRIS approval for CBD product authorization in Mexico.
Canopy Growth - CEO, David Klein.

Canopy Growth shareholders approve Canopy USA asset strategy

After rearranging its capital structure, Canopy Growth (TSX:WEED) will be closer to establishing a U.S.-based multi-state operator.